Financial Summary (All financials)
| In millions, except per share items | Jun-30-14 | Jun-30-13 | Jun-30-12 | Jun-30-11 | Jun-30-10 | Jun-30-09 | Jun-30-08 | Jun-30-07 |
| Revenues | 3,842.0 | 3,550.0 | 3,598.0 | 3,440.0 | 3,377.0 | 3,175.0 | 3,663.0 | 3,478.0 |
| Revenue growth | 8.2% | -1.3% | 4.6% | 1.9% | 6.4% | -13.3% | 5.3% | 14.0% |
| Cost of goods sold | 1,934.0 | 1,700.0 | 1,794.0 | 1,672.0 | 1,686.0 | 1,569.0 | 1,896.0 | 1,911.0 |
| Gross profit | 1,908.0 | 1,850.0 | 1,804.0 | 1,768.0 | 1,691.0 | 1,606.0 | 1,767.0 | 1,567.0 |
| Gross margin | 49.7% | 52.1% | 50.1% | 51.4% | 50.1% | 50.6% | 48.2% | 45.1% |
| Selling, general and administrative | 1,061.0 | 980.0 | 1,033.0 | 1,067.0 | 1,090.0 | 944.0 | 1,027.0 | 890.0 |
| Research and development | 190.0 | 192.0 | 164.0 | 146.0 | 148.0 | 160.0 | 157.0 | 103.0 |
| EBITA | 705.0 | 694.0 | 585.0 | 526.0 | 502.0 | 433.0 | 548.0 | 550.0 |
| EBITA margin | 18.3% | 19.5% | 16.3% | 15.3% | 14.9% | 13.6% | 15.0% | 15.8% |
| Amortization of intangibles | 87.0 | 75.0 | 89.0 | 80.0 | 72.0 | | | |
| EBIT | 618.0 | 619.0 | 496.0 | 446.0 | 430.0 | 433.0 | 548.0 | 550.0 |
| EBIT margin | 16.1% | 17.4% | 13.8% | 13.0% | 12.7% | 13.6% | 15.0% | 15.8% |
| Pre-tax income | 532.0 | 543.0 | 487.0 | 425.0 | 345.0 | 338.0 | 443.0 | 618.0 |
| Income taxes | 115.0 | 154.0 | 126.0 | 126.0 | 184.0 | 51.0 | 110.0 | 116.0 |
| Tax rate | 21.6% | 28.4% | 25.9% | 29.6% | 53.3% | 15.1% | 24.8% | 18.8% |
| Earnings from continuing ops | 417.0 | 389.0 | 361.0 | 299.0 | 161.0 | 287.0 | 333.0 | 502.0 |
| Earnings from discontinued ops | | -4.0 | -68.0 | -50.0 | 33.0 | 568.0 | 330.0 | |
| Net income | 417.0 | 385.0 | 293.0 | 249.0 | 194.0 | 855.0 | 663.0 | 502.0 |
| Net margin | 10.9% | 10.8% | 8.1% | 7.2% | 5.7% | 26.9% | 18.1% | 14.4% |
| |
| Diluted EPS | $1.96 | $1.74 | $1.60 | $1.33 | $0.72 | $1.30 | $1.51 | |
| Shares outstanding (diluted) | 212.9 | 224.0 | 226.0 | 225.1 | 223.0 | 220.5 | 220.5 | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|